SCHEMBL13229792

SCHEMBL13229792

CCC1CNCCCO1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL322796 0.86
SCHEMBL7097741 0.86
Fluoride SCHEMBL7750151 0.86
SCHEMBL3168 0.86
SCHEMBL12524834 0.86
Hydrochloric Acid SCHEMBL3862781 0.84
Ammonia Solution, Strong SCHEMBL331668 0.84
Hydrochloric Acid SCHEMBL18528199 0.84
Water SCHEMBL7481154 0.84
Bromide SCHEMBL1608720 0.84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240409555-A1 CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF NURIX THERAPEUTICS, INC. 2024-12-12 US disclosed
CN-114206855-B Cyanocyclobutyl compounds for Cbl-b inhibition and application thereof 紐力克斯治疗公司 2024-11-26 CN disclosed
US-12049471-B2 Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereof NURIX THERAPEUTICS, INC. (US) 2024-07-30 US disclosed
US-20230212186-A1 CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF NURIX THERAPEUTICS, INC. 2023-07-06 US disclosed
US-11530229-B2 Cyano cyclobutyl compounds for CBL-B inhibition and uses thereof NURIX THERAPEUTICS, INC. (US) 2022-12-20 US disclosed
EP-3969447-A1 CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF Nurix Therapeutics, Inc. (US) 2022-03-23 EP disclosed
CN-114206855-A Cyanocyclobutyl compounds for Cbl-b inhibition and uses thereof 紐力克斯治疗公司 2022-03-18 CN disclosed
US-20210053986-A1 CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF NURIX THERAPEUTICS, INC. 2021-02-25 US disclosed
WO-2021028362-A1 SHP2 INHIBITORS IRBM S.P.A. (IT) 2021-02-18 WO disclosed
EP-3772513-A1 SHP2 INHIBITORS C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening (IT) 2021-02-10 EP disclosed
WO-2020236654-A1 CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF NURIX THERAPEUTICS, INC. (US) 2020-11-26 WO disclosed
US-10030019-B2 Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors FEDORA PHARMACEUTICALS INC. (CA) 2018-07-24 US disclosed
US-8455471-B2 Compositions of CHK1 inhibitors and cyclodextrin ICOS CORPORATION (US) 2013-06-04 US disclosed
US-20100168080-A1 NOVEL COMPOUNDS USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS KHAMRAI UTTAM 2010-07-01 US disclosed
US-20100152160-A1 NOVEL BENZODIOXANE AND BENZOXAZINE DERIVATIVES USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS KHAMRAI UTTAM 2010-06-17 US disclosed